ProShare Advisors LLC trimmed its position in Insys Therapeutics, Inc. (NASDAQ:INSY) by 4.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,145 shares of the specialty pharmaceutical company’s stock after selling 1,864 shares during the period. ProShare Advisors LLC owned about 0.05% of Insys Therapeutics worth $495,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. KCG Holdings Inc. lifted its holdings in Insys Therapeutics by 42.0% in the 1st quarter. KCG Holdings Inc. now owns 26,160 shares of the specialty pharmaceutical company’s stock valued at $275,000 after purchasing an additional 7,735 shares in the last quarter. Schneider Capital Management Corp lifted its holdings in Insys Therapeutics by 33.4% in the 1st quarter. Schneider Capital Management Corp now owns 59,973 shares of the specialty pharmaceutical company’s stock valued at $630,000 after purchasing an additional 15,000 shares in the last quarter. Weiss Multi Strategy Advisers LLC lifted its holdings in Insys Therapeutics by 114.3% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 45,000 shares of the specialty pharmaceutical company’s stock valued at $473,000 after purchasing an additional 24,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Insys Therapeutics by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock valued at $480,000 after purchasing an additional 12,561 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in Insys Therapeutics by 16.9% in the 1st quarter. Tudor Investment Corp ET AL now owns 49,589 shares of the specialty pharmaceutical company’s stock valued at $521,000 after purchasing an additional 7,184 shares in the last quarter. Institutional investors own 25.45% of the company’s stock.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 target price on the stock in a report on Wednesday, July 12th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Piper Jaffray Companies set a $10.00 price objective on shares of Insys Therapeutics and gave the stock a “hold” rating in a report on Wednesday, July 26th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $14.00 price objective on shares of Insys Therapeutics in a report on Friday, June 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $13.25.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/proshare-advisors-llc-sells-1864-shares-of-insys-therapeutics-inc-insy/1611953.html.

In other Insys Therapeutics news, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was purchased at an average cost of $8.93 per share, for a total transaction of $156,275.00. Following the transaction, the insider now owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Saeed Motahari acquired 5,500 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were acquired at an average price of $8.92 per share, with a total value of $49,060.00. Following the completion of the transaction, the chief executive officer now directly owns 15,400 shares in the company, valued at approximately $137,368. The disclosure for this purchase can be found here. Company insiders own 67.90% of the company’s stock.

Insys Therapeutics, Inc. (INSY) opened at 9.11 on Friday. The stock’s market capitalization is $662.26 million. The stock’s 50 day moving average is $9.23 and its 200 day moving average is $11.00. Insys Therapeutics, Inc. has a one year low of $8.68 and a one year high of $15.06.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same period last year, the company posted $0.13 EPS. The business’s quarterly revenue was down 38.4% compared to the same quarter last year. On average, equities analysts forecast that Insys Therapeutics, Inc. will post ($0.29) EPS for the current year.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics, Inc. (NASDAQ:INSY).

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.